111 related articles for article (PubMed ID: 28559557)
1. Deal watch: Neurokinin 3 receptor antagonist revival heats up with Astellas acquisition.
Cully M
Nat Rev Drug Discov; 2017 May; 16(6):377. PubMed ID: 28559557
[No Abstract] [Full Text] [Related]
2. The NK3 Receptor Antagonist ESN364 Suppresses Sex Hormones in Men and Women.
Fraser GL; Ramael S; Hoveyda HR; Gheyle L; Combalbert J
J Clin Endocrinol Metab; 2016 Feb; 101(2):417-26. PubMed ID: 26653113
[TBL] [Abstract][Full Text] [Related]
3. Fezolinetant in the treatment of vasomotor symptoms associated with menopause.
Depypere H; Lademacher C; Siddiqui E; Fraser GL
Expert Opin Investig Drugs; 2021 Jul; 30(7):681-694. PubMed ID: 33724119
[No Abstract] [Full Text] [Related]
4. Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant.
Douxfils J; Beaudart C; Dogné JM
Lancet; 2023 Nov; 402(10413):1623-1625. PubMed ID: 37865107
[No Abstract] [Full Text] [Related]
5. Scaffold hopping of fused piperidine-type NK3 receptor antagonists to reduce environmental impact.
Yamamoto K; Inuki S; Ohno H; Oishi S
Bioorg Med Chem; 2019 May; 27(10):2019-2026. PubMed ID: 30975505
[TBL] [Abstract][Full Text] [Related]
6. Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal.
Gompel A; Stuenkel CA
Cell Rep Med; 2023 Jun; 4(6):101076. PubMed ID: 37343519
[TBL] [Abstract][Full Text] [Related]
7. More promising news (mostly) on manipulating neurokinin B activity as a nonhormonal treatment of hot flashes.
Reame NK
Menopause; 2020 Apr; 27(4):375-376. PubMed ID: 32132443
[No Abstract] [Full Text] [Related]
8. [Molecular modelling and drug design: neurokinin receptor antagonism].
Boudon A; Jacoby E; Michel A
J Pharm Belg; 1997; 52(2):103. PubMed ID: 9296954
[No Abstract] [Full Text] [Related]
9. Fezolinetant findings can fuel future instrumentation inquiries.
Carpenter JS
Menopause; 2020 Dec; 27(12):1347. PubMed ID: 33048862
[No Abstract] [Full Text] [Related]
10. Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms.
Pinkerton JV; Redick DL; Homewood LN; Kaunitz AM
J Clin Endocrinol Metab; 2023 Oct; 108(11):e1448-e1449. PubMed ID: 37097747
[No Abstract] [Full Text] [Related]
11. Rational design of novel pyrrolidine derivatives as orally active neurokinin-3 receptor antagonists.
Ratni H; Ballard TM; Bissantz C; Hoffmann T; Jablonski P; Knoflach F; Knust H; Malherbe P; Nettekoven M; Patiny-Adam A; Riemer C; Schmitt M; Spooren W
Bioorg Med Chem Lett; 2010 Nov; 20(22):6735-8. PubMed ID: 20850972
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in neurokinin receptor antagonists.
Shenvi AB
Curr Top Med Chem; 2003; 3(12):NA. PubMed ID: 12921087
[No Abstract] [Full Text] [Related]
13. Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.
Hanessian S; Babonneau V; Boyer N; Mannoury la Cour C; Millan MJ; De Nanteuil G
Bioorg Med Chem Lett; 2014 Jan; 24(2):510-4. PubMed ID: 24374277
[TBL] [Abstract][Full Text] [Related]
14. Antagonists at the neurokinin receptors--recent patent literature.
Giardina GA; Gagliardi S; Martinelli M
IDrugs; 2003 Aug; 6(8):758-72. PubMed ID: 12917772
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones as NK(1) antagonists.
Seto S; Tanioka A; Ikeda M; Izawa S
Bioorg Med Chem Lett; 2005 Mar; 15(5):1479-84. PubMed ID: 15713411
[TBL] [Abstract][Full Text] [Related]
16. Deal watch: M&A activity in 2009.
Walker J
Nat Rev Drug Discov; 2010 Feb; 9(2):95. PubMed ID: 20118956
[No Abstract] [Full Text] [Related]
17. Deal watch: Synta and Roche collaborate on anti-inflammatory ion channel modulators.
Nat Rev Drug Discov; 2009 Mar; 8(3):184-5. PubMed ID: 19247298
[No Abstract] [Full Text] [Related]
18. Deal watch: Roche deal targets glutamate in neurodevelopmental disorders.
Harrison C
Nat Rev Drug Discov; 2012 Aug; 11(8):590. PubMed ID: 22814417
[No Abstract] [Full Text] [Related]
19. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
Tsuchida H; Takahashi S; Nosaka E; Mukaiyama O; Yamashita M; Morimoto K
Eur J Pharmacol; 2008 May; 586(1-3):306-12. PubMed ID: 18353309
[TBL] [Abstract][Full Text] [Related]
20. Deal watch: Aveo and Astellas to develop VEGF inhibitor for renal cell carcinoma.
Nat Rev Drug Discov; 2011 Apr; 10(4):248. PubMed ID: 21455225
[No Abstract] [Full Text] [Related]
[Next] [New Search]
